CEO COMMENTS
Kristina Torfgård comments Q4 report 2024
“It has been a successful year that has brought us closer to our goal of improving the lives of people living with Parkinson’s disease and other neurodegenerative conditions.”
“I am proud to be part of the IRLAB team and
deeply inspired by the unique combination of ground-breaking research, innovation, and collaboration that permeates the entire company.
Our pipeline is stronger than ever, with our drug
candidates holding the potential to become first-in-class treatments that can transform the lives of millions of people worldwide, along with their loved ones. With the progress we have achieved so far and the exciting opportunities ahead, I confidently look forward to leading IRLAB into the next phase of our growth journey.”
LATEST REPORTS
IRLAB publishes preclinical data on mesdopetam in the esteemed European Journal of Neuroscience
Gothenburg, March 12, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that preclinical data on mesdopetam has been published in the prestigious, peer-reviewed medical journal European Journal of Neuroscience, EJN. The data provide new insights into the system-level mechanisms behind the antidyskinetic effect of mesdopetam and suggest potential additional benefits in the treatment of Parkinson’s related psychosis.
Read More >
Presentation at Redeye’s Theme Event Neurology
Presentation by Kristina Torfgård, CEO, at “Theme Event Neurology”, an event hosted by Redeye, held on October 23, 2024.
Read More >FINANCIAL CALENDAR
NEXT
July 10, 2024
Interim Report January – June 2024